Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
$0.28
+0.1%
$0.26
$0.20
$1.48
$73.31M2.861.82 million shs539,668 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.61
-4.7%
$1.65
$1.40
$7.88
$71.47M1.69339,751 shs372,214 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$4.77
$4.53
$3.13
$26.84
$71.66M2.74292,578 shs132,289 shs
Mannatech, Incorporated stock logo
MTEX
Mannatech
$9.72
+2.3%
$9.77
$6.75
$16.49
$18.47M1.064,442 shs238 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
+0.07%-2.44%+5.65%-52.25%-73.30%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-4.73%-2.42%-9.04%-5.29%-74.80%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
0.00%-5.36%+0.85%-17.76%-80.06%
Mannatech, Incorporated stock logo
MTEX
Mannatech
-1.37%+5.25%-13.64%-14.52%+26.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
3.1239 of 5 stars
4.24.00.00.03.80.80.0
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.9438 of 5 stars
2.03.00.00.03.12.51.3
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.5008 of 5 stars
3.52.00.00.03.61.70.6
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.8975 of 5 stars
0.05.00.00.02.21.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
2.43
Hold$1.52441.68% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.0024.22% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
3.00
Buy$62.221,204.45% Upside
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MTEX, EPIX, JSPR, and ADAP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.00
5/14/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
5/13/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $33.00
4/11/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/1/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.50 ➝ $3.00
3/26/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $1.75
3/21/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.50
3/21/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$3.15 ➝ $1.40
3/11/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
$179.64M0.41N/AN/A$0.17 per share1.65
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.68 per shareN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$7.03 per shareN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
$115.04M0.16N/AN/A$5.64 per share1.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$113.87M-$0.27N/AN/AN/A-25.43%-74.15%-15.09%8/11/2025 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-24.61%-23.87%8/4/2025 (Estimated)
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$64.46M-$5.24N/AN/AN/AN/A-67.64%-58.53%8/12/2025 (Estimated)
Mannatech, Incorporated stock logo
MTEX
Mannatech
-$2.24M-$0.10N/AN/A-1.26%-15.62%-3.76%8/11/2025 (Estimated)

Latest MTEX, EPIX, JSPR, and ADAP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
5/13/2025Q1 2025
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/A-$0.80N/A-$0.80N/A$26.56 million
5/12/2025Q1 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.17-$1.41-$0.24-$1.41N/AN/A
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
3/26/2025Q4 2024
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/A$1.20N/A$1.20N/A$29.01 million
3/24/2025Q4 2024
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$0.17-$0.26-$0.09-$0.29$16.56 million$3.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
$0.202.06%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
0.62
3.85
3.82
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
33.12
33.12
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
7.61
7.61
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.44
1.25
0.74

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
31.37%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%
Mannatech, Incorporated stock logo
MTEX
Mannatech
12.98%

Insider Ownership

CompanyInsider Ownership
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
12.74%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.70%
Mannatech, Incorporated stock logo
MTEX
Mannatech
41.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
490261.52 million224.05 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2015.02 million14.60 millionOptionable
Mannatech, Incorporated stock logo
MTEX
Mannatech
2501.90 million1.10 millionNot Optionable

Recent News About These Companies

Mannatech names Robert Toth vice chairman of the board
Mannatech Inc. Q3 Earnings Summary
Trading (MTEX) With Integrated Risk Controls
(MTEX) Investment Analysis
(MTEX) Trading Signals
How To Trade (MTEX)
(MTEX) Long Term Investment Analysis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.28 +0.00 (+0.07%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.29 +0.01 (+4.89%)
As of 05/27/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.61 -0.08 (-4.73%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.67 +0.06 (+3.73%)
As of 05/27/2025 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$4.77 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.80 +0.03 (+0.61%)
As of 05/27/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Mannatech stock logo

Mannatech NASDAQ:MTEX

$9.72 +0.22 (+2.26%)
Closing price 05/27/2025 03:50 PM Eastern
Extended Trading
$9.72 +0.01 (+0.05%)
As of 05/27/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.